- Home
- DAWN vs AMBQ Comparison
DAWN vs AMBQ Comparison
Compare DAWN & AMBQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- AMBQ
- Stock Information
- Founded
- DAWN 2018
- AMBQ 2010
- Country
- DAWN United States
- AMBQ United States
- Employees
- DAWN N/A
- AMBQ N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- AMBQ Semiconductors
- Sector
- DAWN Health Care
- AMBQ Technology
- Exchange
- DAWN Nasdaq
- AMBQ Nasdaq
- Market Cap
- DAWN 624.8M
- AMBQ 673.1M
- IPO Year
- DAWN 2021
- AMBQ 2025
- Fundamental
- Price
- DAWN $7.47
- AMBQ $29.70
- Analyst Decision
- DAWN Strong Buy
- AMBQ Buy
- Analyst Count
- DAWN 7
- AMBQ 4
- Target Price
- DAWN $27.86
- AMBQ $43.75
- AVG Volume (30 Days)
- DAWN 1.5M
- AMBQ 219.8K
- Earning Date
- DAWN 10-30-2025
- AMBQ 11-06-2025
- Dividend Yield
- DAWN N/A
- AMBQ N/A
- EPS Growth
- DAWN N/A
- AMBQ N/A
- EPS
- DAWN N/A
- AMBQ N/A
- Revenue
- DAWN $187,638,000.00
- AMBQ $74,210,000.00
- Revenue This Year
- DAWN $12.96
- AMBQ N/A
- Revenue Next Year
- DAWN $48.40
- AMBQ $25.34
- P/E Ratio
- DAWN N/A
- AMBQ N/A
- Revenue Growth
- DAWN 2190.50
- AMBQ N/A
- 52 Week Low
- DAWN $5.64
- AMBQ $28.61
- 52 Week High
- DAWN $16.76
- AMBQ $51.76
- Technical
- Relative Strength Index (RSI)
- DAWN 53.82
- AMBQ N/A
- Support Level
- DAWN $6.99
- AMBQ N/A
- Resistance Level
- DAWN $7.73
- AMBQ N/A
- Average True Range (ATR)
- DAWN 0.44
- AMBQ 0.00
- MACD
- DAWN 0.02
- AMBQ 0.00
- Stochastic Oscillator
- DAWN 48.73
- AMBQ 0.00
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.